ReCode Therapeutics to Participate in Upcoming Investor Conferences - Feb 16, 2021
MENLO PARK, Calif. & DALLAS--(BUSINESS WIRE)-- ReCode Therapeutics™ (ReCode) (the Company), a private biopharmaceutical company pioneering disease-modifying medicines for the treatment of life-limiting respiratory diseases, today announced that members of the executive team will be participating in three upcoming virtual investor conferences. Details of the events are as follows:
- BIO CEO and Investor Digital Conference
Date: Feb. 17, 2021
Time: 3:00 - 4:00 pm ET
David Lockhart, CEO and President, will participate in the panel session: Turning RNA Research into Medicines.
The session will be available through the BIO CEO & Investor Digital Conference website and available on demand to registered participants for approximately 30 days following the event. The company will also make the recording available on the ReCode website in the near future.
- Cowen and Company’s 41st Annual Health Care Conference
Date: March 1- 4, 2021
Virtual 1X1 meetings
- H.C. Wainwright’s Global Life Sciences Conference
Date: March 4, 2021
Time: 4:00-4:30 pm ET
David Lockhart, CEO and President will participate in a fireside chat with Andrew Fein, Managing Director, Equity Research at H.C. Wainwright & Co.
About ReCode Therapeutics
ReCode Therapeutics is an integrated genetic medicines company developing targeted, disease-modifying therapies for patients with life-limiting respiratory diseases. Powered by its proprietary lipid nanoparticle (LNP) platform, the Company’s pipeline includes lead programs for patients living with cystic fibrosis (CF) and primary ciliary dyskinesia (PCD). The Company is leveraging its LNPs and nucleic acid technologies across multiple modalities, including mRNA-mediated replacement therapies, first-in-class tRNAs and systemic delivery of gene editing components to target cells and tissues. For more information, visit www.recodetx.com and follow us on Twitter @ReCodeTx and LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005419/en/
Source: ReCode Therapeutics
View this news release online at: